Can You Take Bromfenac with Gleolan?

Food significantly decreases the levels of bromfenac. Avoid eating a high-fat meal. Take bromfenac on an empty stomach at least 30 minutes before or 2 hours after a meal. This will make it easier for your body to absorb the medication.

Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can develop at any time, with or without warning symptoms. NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as: prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy. Particular vigilance is necessary when treating older adult or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.

The use aminolevulinic acid (ALA) oral solution is contraindicated in patients with acute or chronic types of porphyria, due to potential ineffectiveness of the drug in these patients.

Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Caution is advised in patients with hyperkalemia.

The effect of hepatic impairment on the pharmacokinetics of aminolevulinic acid (ALA) oral solution is unknown. The contribution of the liver to the elimination of ALA is unknown. ALA clearance may be reduced in patients with hepatic impairment. Care should be exercise when administering this agent in patients with liver impairment as it is not known if dose adjustment is needed.

Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Caution is advised in patients with hyperkalemia.

The effect of renal impairment on the pharmacokinetics of aminolevulinic acid (ALA) oral solution is unknown. Approximately one third of the ALA dose is excreted in urine as parent drug and drug clearance may be reduced in patients with renal impairment. Care should be exercise when administering this agent in patients with renal impairment as it is not known if dose adjustment is needed.